Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

13.85 -0.57

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.69

Max

14.37

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.4M -14M
EPS	-0.15
Angestellte	37
EBITDA	312K -12M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+126.85% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-223M 1.1B
Vorheriger Eröffnungskurs	14.42
Vorheriger Schlusskurs	13.85

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Aug. 2026, 23:56 UTC

Cooper Companies Inc. shares are roughly flat in after-market trading. Market sentiment reflects concerns from a disappointing ADP employment report showing weak job growth.

5. Aug. 2026, 23:56 UTC

News

CACI International reported Q2 sales of $2.71 billion, exceeding expectations. Shares advanced in after-market trading following strong earnings and optimistic full-year guidance.

5. Aug. 2026, 23:56 UTC

CEVA Inc shares rose during after-market hours after earlier declines. Broader market sentiment was affected by a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Correlated Moves

Shares of KKR & Co Inc are lower in after-market trading, following volatility and a disappointing ADP employment report indicating weak job growth.

5. Aug. 2026, 23:56 UTC

L3Harris Technologies shares are higher in after-market hours, despite no specific news. Cautious sentiment follows a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Allison Transmission Holdings Inc shares are higher in after-market trading, reaching a high above the 20-day moving average amid a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Flex Ltd shares are higher in after-market hours, despite no specific news. Market sentiment reflects concerns from a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Correlated Moves

Ennis Inc shares declined in after-market trading, reflecting broader market sentiment following a disappointing ADP employment report indicating weak job growth.

5. Aug. 2026, 23:56 UTC

Correlated Moves

News

Social Media

Magnolia Oil & Gas reported net income of $181.8 million and adjusted EPS of $0.99, exceeding estimates, contributing to after-market gains.

5. Aug. 2026, 23:56 UTC

Correlated Moves

News

Entergy Corp shares rose in after-market trading, supported by a $35 million contract awarded to ICF for energy efficiency programs.

5. Aug. 2026, 23:56 UTC

Tyler Technologies shares advanced in after-hours trading, recovering from an earlier dip. The stock is positioned near the midpoint of its one-month trading range.

5. Aug. 2026, 23:56 UTC

Charles River Laboratories is higher in after-market hours, recovering from session lows. Broader market sentiment is affected by a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Corsair Gaming Inc shares are higher in after-market trading, reflecting strong performance despite a disappointing ADP employment report affecting market sentiment.

5. Aug. 2026, 23:56 UTC

Public Service Enterprise Group shares are higher in after-market trading amid broader market concerns from a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Sweetgreen Inc. shares are trading lower in after-market hours, reflecting broader market sentiment following a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Correlated Moves

Cheesecake Factory shares decline in after-market trading, retracing earlier gains amid broader market caution following a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

5. Aug. 2026, 23:56 UTC

Correlated Moves

News

Uranium Energy Corp gains in after-market trading, influenced by Cameco's rise amid cautious market sentiment following a weak ADP employment report.

5. Aug. 2026, 23:56 UTC

Correlated Moves

Ultra Clean Holdings shares rose in after-market hours, supported by a significant gain in Veeco Instruments. Broader market sentiment was affected by a weak ADP report.

5. Aug. 2026, 23:56 UTC

Snap Inc. shares are lower in after-market trading, with no specific news identified. Broader market sentiment is affected by a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

NIO Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment is affected by a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Aaon Inc. shares are lower in after-market hours, influenced by a disappointing ADP employment report showing only 44,000 private sector jobs added in July.

5. Aug. 2026, 23:56 UTC

Correlated Moves

Social Media

Micron Technology Inc shares are lower in after-market hours, following a decline earlier. The stock's movement aligns with Western Digital's significant drop.

5. Aug. 2026, 23:56 UTC

Chipotle Mexican Grill shares were roughly flat in after-market trading. Broader market sentiment was influenced by a disappointing ADP employment report.

5. Aug. 2026, 23:56 UTC

Ionis Pharmaceuticals shares are lower in after-market hours, influenced by a disappointing ADP employment report revealing only 44,000 private sector jobs added in July.

5. Aug. 2026, 23:56 UTC

Twist Bioscience Corp shares rose in after-market trading, despite earlier declines. Market sentiment was affected by a disappointing ADP employment report.

5. Aug. 2026, 23:51 UTC

PulteGroup Inc. shares declined in after-market trading, reversing earlier gains amid cautious sentiment following disappointing U.S. employment data from the ADP report.

5. Aug. 2026, 23:51 UTC

Travelers Companies Inc. shares are lower in after-market trading, following weak private sector employment growth data from the ADP report.

5. Aug. 2026, 23:51 UTC

Correlated Moves

Kimco Realty Corp shares are higher in after-market trading, influenced by the broader real estate sector despite recent economic data indicating slower job growth.

5. Aug. 2026, 23:51 UTC

News

Global Net Lease raised its 2026 FFO guidance to $0.82-$0.85, aligning with estimates, contributing to after-market gains following its earnings report.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

126.85% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD 126.85%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.